In a bid to expand its innovation capability, Entod Pharmaceuticals opened a research and development (R&D) facility in Navi Mumbai. The centre will focus on new product development, formulation and molecular research in dermatology, ophthalmic and ENT.
The Department of Scientific and Industrial Research approved the research facility in Navi Mumbai and it was inaugurated by Entod Pharmaceuticals group chairman Kishore Masurkar. The latest facility includes advanced equipment and analytical and formulation research tools.
Nikkhil K Masurkar, Entod Pharmaceuticals CEO, reportedly said the latest R&D facility will allow the company to manufacture “life-changing medicines” to patients. It will also help chart the company’s growth.
Indian pharmaceuticals should focus on expanding their R&D and inventions to advance their businesses, Nikkhil K Masurklar said, adding that India’s G20 presidency will likely encourage innovation and increase the numbers of researchers. This will also aid in public and private spending on R&D.
Late last year, Entod Pharmaceuticals’ Entod Beauty London launched a synthetic snake venom-based face serum, Vasuki, in India. The company claimed that the serum was the world’s first clinically proven synthetic tripeptide snake venom neurotoxin.